First Cetuximab Biosimilar Debuts In India; Merck KGaA Sticks To Guns
Executive Summary
Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.